@StableBread hmm 7% Revenue for 2026 is really way low ..hope it will be at least 20% for 2026,,did management said this in last ER?i could not find @KabraxFX@StableBread@bjmtweets
So why did the stock get cut in half?
Growth deceleration. When $ROOT was trading near $80, the bull case assumed ~50% annual premium growth through 2027.
FY2025 (reported February 25, 2026) came in at 29%, which is still strong for an insurer but well below that trajectory.
Q4 2025 (reported the same date) was worse. Gross premiums written grew 9% y/y, net income dropped to $5M, and the net combined ratio spiked to 99.7%.
That's an 8.2 percentage point jump from Q4 2024's 91.5%.
Management attributed the weakness to elevated seasonality and deliberate investment in distribution and tech. Reasonable, but it means $ROOT is spending more to grow slower.
Revenue consensus for 2026 is ~$1.62B, implying ~7% growth. A big slowdown from 29%.
$ROOT dropped from $80 to $43 in six months.
But the business actually got better. First full-year profit, $206M in free cash flow, $669M in cash.
However, the market wanted 50% growth. It got 29%. Here's the story: ↓
PORTFOLIO UPDATE
$VOO: -6% YTD
$QQQ: -7.5% YTD
Me: -14% YTD
The portfolio is still getting hammered YTD, which is no surprise since I've been buying companies that are very out of favor with the market currently.
Since my last update I started a new position in $MELI. I've been building this position heavily this month and would like to to eventually be at least 8% allocation.
There aren't any other positions I'm currently planning to open, but I am keeping my eye on $DLO $WM $AVGO and a few others.
It's very likely this correction keeps going and I'm here for it! Lots of great opportunities out there.
@DaSteeringWheel Who cares I don’t look at my stocks daily or even weekly. The lower it goes for no reason the better bc they are buying back shares, hope it goes bellow $10 tbh
@Arne19288930 I actually owned the shares and sold them for a tiny loss. It’s an interesting company and the ceo seems ambitious, but unfortunately I do not have any advantage in insurance. So at the end of the day, “too hard pile”
$LLY has received FDA approval for Foundayo (orforglipron), its once-daily oral GLP-1 for weight loss.
Key points:
• can be taken any time of day
• no food or water restrictions
• available via LillyDirect from April 6
• pricing starts at $25/month with coverage and $149 self-pay
#stocks#Investing
I’m done.
Stock picking isn’t for me. I can’t stand watching my account go down and second guessing all my decisions.
It’s too much work just for a chance at outperformance.
No one beats the market anyways. It’s a fools game.
I’m just gonna go $VOO and chill from now on.
It's over.
@NotA_Bull but do you think $SBUX still has growth and moat, as we see lot of alternative local coffee franchise are opening up and surprisingly the response was really good for those.
If you're not sure where to start, invest in companies you see in your daily life. Check out this example …
I woke up today and checked my $AAPL iPhone. I headed over to $SBUX for a coffee, and since I wasn't carrying any cash, I just swiped my $V card.
On the way to the gym, I grabbed a $MNST to get moving, then put in a solid session at $PLNT.
Once I got home, I knocked out some work on my $MSFT laptop using $GOOGL Workspace. To wind down, I spent some time scrolling through $META and ended the night watching a movie on $NFLX.
Now, picture owning this portfolio:
$AAPL, $SBUX, $V, $MNST, $PLNT, $MSFT, $GOOGL, $META, $NFLX.